Methods and composition for a binding molecule targeting cancer cells expressing SSX2 peptide 41-49 in HLA-A*0201 context
Disclosed are Synovial Sarcoma X breakpoint 2 binding molecules and methods for their use in the detection and treatment of cancer.
1. A Synovial Sarcoma X breakpoint 2 (SSX2) binding molecule comprising:
(i) 3 complementarity determining regions (CDRs) from the light chain variable region, wherein
the first CDR comprises the sequence set forth in SEQ ID NO: 1,
the second CDR comprises the sequence set forth in SEQ ID NO: 2, and
the third CDR comprises the sequence set forth in SEQ ID NO: 3; and
(ii) 3 CDRs from the heavy chain variable region, wherein
the first CDR comprises the sequence set forth in SEQ ID NO: 4,
the second CDR comprises the sequence set forth in SEQ ID NO: 5, and
the third CDR comprises the sequence set forth in SEQ ID NO: 6;
wherein the binding molecule targets a SSX2 peptide 41-49 (SEQ ID NO:07).
2. The SSX2 binding molecule of claim 1 , wherein the binding molecule targets the SSX2 peptide 41-49 (SEQ ID NO: 7) in the context of human leukocyte antigen (HLA)-A*0201.
3. The SSX2 binding molecule of claim 1 , wherein the binding molecule is an antibody, diabody, triabody, antigen binding fragment, bi-specific killer engager (BIKE), or tri-specific killer engager (TriKE).
4. The SSX2 binding molecule of claim 3 , wherein the antibody is of IgG1, IgG2, IgG3, IgG4, IgM or IgA isotype.
5. A chimeric antigen receptor (CAR) comprising the Synovial Sarcoma X breakpoint 2 (SSX2) binding molecule of claim 1 .
6. The CAR of claim 5 , further comprising one or more activating intra-cellular domains derived from CD3zeta, CD28, 4-1BB, OX40L or 2B4.
7. A cell comprising the CAR of claim 5 , wherein the cell is a T cell or NK cell.